TOP TEN perturbations for NM_000324 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000324
Selected probe(set): 206145_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000324 (206145_at) across 5392 perturbations tested by GENEVESTIGATOR:

B-CLL study 5 / normal bone marrow sample

Relative Expression (log2-ratio):-6.212538
Number of Samples:441 / 74
Experimental B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

precursor-B-ALL study 1 (t(11q23)) / normal bone marrow sample

Relative Expression (log2-ratio):-5.0616665
Number of Samples:70 / 74
Experimental precursor-B-ALL study 1 (t(11q23))
Bone marrow samples of patients with precursor B-ALL (t(11q23)/MLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

AML study 1 (t(8;21)(q22;q22)) / normal bone marrow sample

Relative Expression (log2-ratio):-5.0264425
Number of Samples:40 / 74
Experimental AML study 1 (t(8;21)(q22;q22))
Bone marrow samples of patients with acute myeloid leukemia (AML) with genetic aberration (t(8;21)(q22;q22)).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

AML study 1 (t(11q23)) / normal bone marrow sample

Relative Expression (log2-ratio):-4.807867
Number of Samples:38 / 74
Experimental AML study 1 (t(11q23))
Bone marrow samples of patients with acute myeloid leukemia (AML) with genetic aberration (t(11q23)/MLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

T-ALL study 1 / normal bone marrow sample

Relative Expression (log2-ratio):-4.439458
Number of Samples:174 / 74
Experimental T-ALL study 1
Bone marrow samples of patients with T-ALL.
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

c-ALL/pre-B-ALL study 1 (t(9;22)(q34,q11)) / normal bone marrow sample

Relative Expression (log2-ratio):-4.43556
Number of Samples:121 / 74
Experimental c-ALL/pre-B-ALL study 1 (t(9;22)(q34,q11))
Bone marrow samples of patients with c-ALL/pre-B-ALL (t(9;22)(q34,q11)/BCR-ABL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

AML study 1 (t(15;17)(q22;q11-12)) / normal bone marrow sample

Relative Expression (log2-ratio):-4.435196
Number of Samples:36 / 74
Experimental AML study 1 (t(15;17)(q22;q11-12))
Bone marrow samples of patients with acute promyelocytic leukemia [subtype of acute myeloid leukemia (AML)] with genetic aberration (t(15;17)(q22;q11-12)/PML-RAR? and variations).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

precursor-B-ALL study 1 (t(1;19)(q23,q13)) / normal bone marrow sample

Relative Expression (log2-ratio):-4.397814
Number of Samples:36 / 74
Experimental precursor-B-ALL study 1 (t(1;19)(q23,q13))
Bone marrow samples of patients with precursor B-ALL (t(1;19)(q23,q13)/E2A-PBX1).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

AML study 1 (inv(16)/t(16;16)) / normal bone marrow sample

Relative Expression (log2-ratio):-4.3146257
Number of Samples:28 / 74
Experimental AML study 1 (inv(16)/t(16;16))
Bone marrow samples of patients with acute myeloid leukemia (AML) with genetic aberration (inv(16)/t(16;16)).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

sickle cell disease study 2 (Globin red.) / normal blood sample

Relative Expression (log2-ratio):4.234563
Number of Samples:5 / 5
Experimental sickle cell disease study 2 (Globin red.)
Whole blood samples of patients with sickle cell disease collected in PAXgene tubes. RNA was extracted using the PAXgene? Blood RNA System Kit followed by an on-column DNase digestion. Then globin mRNA was depleted using the GLOBINclear?-Human kit.
Control normal blood sample
Whole blood samples of healthy volunteers collected in PAXgene tubes. RNA was extracted using the PAXgeneTM Blood RNA System Kit including an on-column DNase digestion. Then globin mRNA was depleted using the GLOBINclearTM-Human kit.